404 polymorphisms on the survival of colorectal cancer patients receiving ad- juvant 5-fluorouracil. Pharmacogenet Genomics 2005;15:723–730. 116 Roth AD, Tejpar S, Yan P et al. Tissue biomarkers (BIOM) in colon can- cer (COC): The translational study on the randomized phase III trial com- paring infused irinotecan/5-fluorouracil (5-FU)/folinic acid (FA) to 5-FU/FA in stage II-III COC patients (pts) [abstract 4022]. J Clin Oncol 2007;25:169s (updated information presented at the meeting). 117 Vivanco I, Sawyers CL. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer 2002;2:489 –501. 118 Hayes DF, Bast RC, Desch CE et al. Tumor marker utility grading system: A framework to evaluate clinical utility of tumor markers. J Natl Cancer Inst 1996;88:1456 –1466. 119 McShane LM, Altman DG, Sauerbrei W et al. Reporting recommenda- tions for tumor marker prognostic studies (REMARK). J Natl Cancer Inst 2005;97:1180 –1184. 120 Deutsch EW, Ball CA, Berman JJ et al. Minimum information specifica- tion for in situ hybridization and immunohistochemistry experiments (MISFISHIE). Nat Biotechnol 2008;26:305–312. 121 Nakao K, Mehta KR, Fridlyand J et al. High-resolution analysis of DNA copy number alterations in colorectal cancer by array-based comparative genomic hybridization. Carcinogenesis 2004;25:1345–1357. 122 Lips EH, van Eijk R, de Graaf EJ et al. Progression and tumor heteroge- neity analysis in early rectal cancer. Clin Cancer Res 2008;14:772–781. 123 Oosting J, Lips EH, van Eijk R et al. High-resolution copy number anal- ysis of paraffin-embedded archival tissue using SNP BeadArrays. Ge- nome Res 2007;17:368 –376. 124 Thomas RK, Baker AC, Debiasi RM et al. High-throughput oncogene mu- tation profiling in human cancer. Nat Genet 2007;39:347–351. 125 Farragher SM, Tanney A, Kennedy RD et al. RNA expression analysis from formalin fixed paraffin embedded tissues. Histochem Cell Biol 2008;130:435– 445. 126 Devries S, Nyante S, Korkola J et al. Array-based comparative genomic hybridization from formalin-fixed, paraffin-embedded breast tumors. J Mol Diagn 2005;7:65–71. 127 Hoshida Y, Villanueva A, Kobayashi M et al. Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med 2008;359: 1995–2004. 128 Clark-Langone KM, Wu JY, Sangli C et al. Biomarker discovery for colon cancer using a 761 gene RT-PCR assay. BMC Genomics 2007;8:279. 129 Braun MS, Richman SD, Quirke P et al. Predictive biomarkers of chemo- therapy efficacy in colorectal cancer: Results from the UK MRC FOCUS trial. J Clin Oncol 2008;26:2690 –2698. 130 Yu J, Shannon WD, Watson MA et al. Gene expression profiling of the iri- notecan pathway in colorectal cancer. Clin Cancer Res 2005;11:2053–2062. 131 Swanton C, Marani M, Pardo O et al. Regulators of mitotic arrest and cer- amide metabolism are determinants of sensitivity to paclitaxel and other chemotherapeutic drugs. Cancer Cell 2007;11:498 –512. 132 Swanton C, Nicke B, Marani M et al. Initiation of high frequency multi- drug resistance following kinase targeting by siRNAs. Cell Cycle 2007; 6:2001–2004. 133 Swanton C, Tomlinson I, Downward J. Chromosomal instability, colorec- tal cancer and taxane resistance. Cell Cycle 2006;5:818 – 823. 134 Bild AH, Yao G, Chang JT et al. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 2006;439:353–357. 135 Potti A, Dressman HK, Bild A et al. Genomic signatures to guide the use of chemotherapeutics. Nat Med 2006;12:1294 –1300. Biomarkers in Colon Cancer Adjuvant Treatment 136 Dressman HK, Berchuck A, Chan G et al. An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer. J Clin Oncol 2007;25:517–525. 137 Salter KH, Acharya CR, Walters KS et al. An integrated approach to the prediction of chemotherapeutic response in patients with breast cancer. PLoS ONE 2008;3:e1908. 138 Perou CM, Sørlie T, Eisen MB et al. Molecular portraits of human breast tumours. Nature 2000;406:747–752. 139 Sørlie T, Perou CM, Tibshirani R et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001;98:10869 –10874. 140 van de Vijver MJ, He YD, van’t Veer LJ et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002;347:1999 – 2009. 141 Buyse M, Loi S, van’t Veer L et al. Validation and clinical utility of a 70- gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst 2006;98:1183–1192. 142 Foekens JA, Atkins D, Zhang Y et al. Multicenter validation of a gene expression-based prognostic signature in lymph node-negative primary breast cancer. J Clin Oncol 2006;24:1665–1671. 143 Paik S, Shak S, Tang G et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004;351: 2817–2826. 144 Ma X, Hilsenbeck S, Wang W et al. The HOXB13:IL17BR expression index is a prognostic factor in early-stage breast cancer. J Clin Oncol 2006;24:4611– 4619. 145 Chang HY, Nuyten DS, Sneddon JB et al. Robustness, scalability, and in- tegration of a wound-response gene expression signature in predicting breast cancer survival. Proc Natl Acad Sci U S A 2005;102:3738 –3743. 146 Fan C, Oh DS, Wessels L et al. Concordance among gene-expression- based predictors for breast cancer. N Engl J Med 2006;355:560 –569. 147 Wirapati P, Sotiriou C, Kunkel S et al. Meta-analysis of gene expression profiles in breast cancer: Toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res 2008;10:R65. 148 Sotiriou C, Wirapati P, Loi S et al. Gene expression profiling in breast cancer: Understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 2006;98:262–272. 149 Wang Y, Jatkoe T, Zhang Y et al. Gene expression profiles and molecular markers to predict recurrence of Dukes’ B colon cancer. J Clin Oncol 2004;22:1564 –1571. 150 Barrier A, Boelle PY, Roser F et al. Stage II colon cancer prognosis pre- diction by tumor gene expression profiling. J Clin Oncol 2006;24:4685– 4691. 151 Michiels S, Koscielny S, Hill C. Interpretation of microarray data in can- cer. Br J Cancer 2007;96:1155–1158. 152 Kim GP, Colangelo LH, Wieand HS et al. Prognostic and predictive roles of high-degree microsatellite instability in colon cancer: A National Can- cer Institute-National Surgical Adjuvant Breast and Bowel Project collab- orative study. J Clin Oncol 2007;25:767–772. 153 Deschoolmeester V, Van Damme N, Baay M et al. Microsatellite insta- bility in sporadic colon carcinomas has no independent prognostic value in a Belgian study population. Eur J Cancer 2008;44:2288 –2295. 154 Lanza G, Matteuzzi M, Gafa R et al. Chromosome 18q allelic loss and prognosis in stage II and III colon cancer. Int J Cancer 1998;79:390 – 395.